HB 354 (see companion bill HB 449) – Alabama
Introduced: 2019 Status: Inactive / Dead
Pharmacists, biological drug products, substitution with interchangeable biological products as defined, Sec. 34-23-8.1 added; Sec. 34-23-1 am’d.
HB 3583 – Illinois
Introduced: 2021 Status: Inactive / Dead
Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the …
HB 3630 (see companion bill SB 2008) – Illinois
Introduced: 2021 Status: Inactive / Dead
Amends the Illinois Insurance Code. Provides that if a generic equivalent for a brand name drug is approved by the federal Food and Drug Administration, plans that provide coverage for prescription drugs through the use …
HB 3791 – Oklahoma
Introduced: 2020 Status: Inactive / Dead
Pharmacy; interchangeable biological products; effective date. The CS to HB 3791 allows pharmacists to substitute a prescribed biological product for a FDAapproved interchangeable substitute, provided the prescribing physician has allowed the substitution and the pharmacy …
HB 3972 – Illinois
Introduced: 2023 Status: In Process
Amends the Illinois Procurement Code. Provides that the Department of Central Management Services, in consultation with the Chief Procurement Officer, shall implement and develop a program to establish a State prescription generic drug label for …
HB 403 – Louisiana
Introduced: 2023 Status: Enacted
Authorizes substitution of certain biosimilar biological products relative to step therapy or fail first protocols
HB 4352 – Michigan
Introduced: 2021 Status: Enacted Year Enacted: 2022
House Bill 4352 would amend the Public Health Code. Currently under the code, if a pharmacist who sells drugs at retail is asked, he or she must provide the current selling price of a drug …
HB 4472 – Michigan
Introduced: 2017 Status: Enacted Year Enacted: 2018
TO ALLOW PHARMACISTS TO DISPENSE FDA-DESIGNATED INTERCHANGEABLE BIOLOGICAL DRUG PRODUCTS: When a pharmacist receives a prescription for a brand name drug product or biological drug product, the pharmacist may dispense a lower cost but not …
HB 449 (see companion bill HB 354) – Alabama
Introduced: 2019 Status: Inactive / Dead
Pharmacists, biological drug products, substitution with interchangeable biological products as defined, Sec. 34-23-8.1 added; Sec. 34-23-1 am’d.
HB 4524 – West Virginia
Introduced: 2018 Status: Enacted
This bill requires a pharmacist who receives a prescription for a specific biological product to select a less expensive interchangeable biological product, unless, in the exercise of his or her professional judgment, the pharmacist believes …
HB 4890 – Michigan
Introduced: 2023 Status: In Process
Health: pharmaceuticals; insulin production program; establish.
HB 4900 – Illinois
Introduced: 2018 Status: Inactive / Dead
ILLINOIS GENERIC DRUG PRICING FAIRNESS ACT: Provides that a manufacturer or wholesale drug distributor shall not engage in price gouging in the sale of an essential off-patent or generic drug. Provides that the Director of …
HB 631 – Maryland
Introduced: 2017 Status: Enacted
Note: In April 2018, the 4th U.S. Circuit Court of Appeals found HB 631 unconstitutional because it violates the dormant commerce clause. In Feb. 2019, the Supreme Court denied certiorari for Maryland’s appeal, so HB …
HB 6619 – Connecticut
Introduced: 2023 Status: Inactive / Dead
An Act concerning prohibiting pay for delay. To preserve consumer access to affordable generic drugs.
HB 664 – Maryland
Introduced: 2020 Status: Inactive / Dead
Pharmacists – Required Notification and Authorized Substitution – Lower-Costing Drugs, Medical Devices, and Biological Products. Requiring a pharmacist or a pharmacist’s designee who is under certain supervision to inform a certain consumer of the availability …
HB 69 – Alabama
Introduced: 2019 Status: Enacted
Relating to prescriptions; to amend Section 34-23-8, Code of Alabama 1975, to provide that an electronic prescription from a practitioner specify whether a generic product may be dispensed.